<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02054637</url>
  </required_header>
  <id_info>
    <org_study_id>PHV106-B.05</org_study_id>
    <nct_id>NCT02054637</nct_id>
  </id_info>
  <brief_title>Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy</brief_title>
  <official_title>Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Somatostatine induces a dose-dependent reduction of postprandial plasma cholecystokinin (CCK)
      secretion with a concomitant inhibition of postprandial gallbladder contraction, abolishing
      almost completely bile salts output from the gallbladder. Somatostatine is also known to
      decrease acid production with significant increase of intragastric pH. In this way,
      somatostatine could influence acid as well as non-acid reflux by decreasing gallbladder
      emptying and decreasing acid secretion.

      Purpose of the study is to evaluate the efficacy of lanreotide autogel 120 mg on symptoms and
      endoscopic lesions in patients with an endoscopic gastrointestinal reflux esophagitis that
      cannot be controlled with classic therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients presenting with persistent esophagitis on endoscopy while on proton pump inhibitors
      (PPI) treatment will receive a maximal therapy consisting of 2 x 40 mg of PPI before the
      meals (morning and evening) and a H2 blocker before bedtime (standard practice). They will be
      reevaluated endoscopically and clinically 2 months later (standard practice). If reflux
      persists, objectivized by impedancemetry (standard practice), they will be asked to
      participate in this study.

      Lanreotide autogel 120 mg deep subcutaneously every 4 weeks will be added to the treatment. A
      total of 3 injections per patient have been foreseen in this proof of concept study.

      Patients will be reevaluated clinically after 2, 4 and 8 weeks. At the end of the study a new
      upper gastrointestinal endoscopy and impedancemetry will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Los Angeles criteria for reflux esophagitis</measure>
    <time_frame>4 weeks after the last injection with lanreotide</time_frame>
    <description>Endoscopy at the start of the study will be compared with endoscopy at the end of the study.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Acid Reflux Esophagitis</condition>
  <condition>Non-acid Reflux Esophagitis</condition>
  <arm_group>
    <arm_group_label>Lanreotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lanreotide autogel 120mg injection every 4 weeks (every patient will receive 3 injections)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanreotide</intervention_name>
    <arm_group_label>Lanreotide</arm_group_label>
    <other_name>Somatuline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persistent endoscopic reflux in spite of maximal medical therapy with PPI 2 x 40 mg
             (before breakfast and dinner) and 300 mg of H2 blocker ranitidine (at bedtime).

        The Los Angeles classification (LA) will be used to evaluate endoscopic reflux. Any distal
        esophageal ulcer with negative biopsy is also diagnostic for reflux.

        Persistent reflux is defined as:

        No reflux complaints but continuing endoscopic lesions and positive impedancemetry.

        Reflux complaints with continuing endoscopic lesions and positive impedancemetry.

        Reflux complaints without endoscopic lesions but positive impedancemetry.

        Exclusion Criteria:

          -  Pregnancy or inadequate anticonception, breast feeding.

          -  Negative impedancemetry.

          -  Diabetes.

          -  Placement of a gastric ring for weight loss.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Moubax, Assistent</last_name>
    <role>Study Chair</role>
    <affiliation>University hospital of Brussels, Laarbeeklaan, Jette</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kim Moubax, Assistent</last_name>
    <phone>003224749346</phone>
    <phone_ext>0032476486103</phone_ext>
    <email>kimmoubax970@hotmail.com/kim.moubax@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniël Urbain, Professor</last_name>
    <email>daniel.urbain@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Brussels</name>
      <address>
        <city>Jette</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Moubax, Assistent</last_name>
      <phone>003224749346</phone>
      <phone_ext>0032476486103</phone_ext>
      <email>kimmoubax970@hotmail.com/kim.moubax@uzbrussel.be</email>
    </contact>
    <contact_backup>
      <last_name>Daniël Urbain, Professor</last_name>
      <email>daniel.urbain@uzbrussel.be</email>
    </contact_backup>
    <investigator>
      <last_name>kim moubax, assistent</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Ishikawa M, Kitayama J, Kaizaki S, Nakayama H, Ishigami H, Fujii S, Suzuki H, Inoue T, Sako A, Asakage M, Yamashita H, Hatono K, Nagawa H. Prospective randomized trial comparing Billroth I and Roux-en-Y procedures after distal gastrectomy for gastric carcinoma. World J Surg. 2005 Nov;29(11):1415-20; discussion 1421.</citation>
    <PMID>16240061</PMID>
  </reference>
  <reference>
    <citation>Montesani C, D'Amato A, Santella S, Pronio A, Giovannini C, Cristaldi M, Ribotta G. Billroth I versus Billroth II versus Roux-en-Y after subtotal gastrectomy. Prospective [correction of prespective] randomized study. Hepatogastroenterology. 2002 Sep-Oct;49(47):1469-73.</citation>
    <PMID>12239969</PMID>
  </reference>
  <reference>
    <citation>Gerard PS, Gerczuk P, Finestone H. Bile reflux in the esophagus demonstrated by HIDA scintigraphy. Clin Nucl Med. 2007 Mar;32(3):224-5.</citation>
    <PMID>17314604</PMID>
  </reference>
  <reference>
    <citation>Swartz DE, Mobley E, Felix EL. Bile reflux after Roux-en-Y gastric bypass: an unrecognized cause of postoperative pain. Surg Obes Relat Dis. 2009 Jan-Feb;5(1):27-30. doi: 10.1016/j.soard.2008.10.009. Epub 2008 Oct 30.</citation>
    <PMID>19095503</PMID>
  </reference>
  <reference>
    <citation>Gans SL, van Westreenen HL, Kiewiet JJ, Rauws EA, Gouma DJ, Boermeester MA. Systematic review and meta-analysis of somatostatin analogues for the treatment of pancreatic fistula. Br J Surg. 2012 Jun;99(6):754-60. doi: 10.1002/bjs.8709. Epub 2012 Mar 20. Review.</citation>
    <PMID>22430616</PMID>
  </reference>
  <reference>
    <citation>Drewe J, Sieber CC, Mottet C, Wullschleger C, Larsen F, Beglinger C. Dose-dependent gastrointestinal effects of the somatostatin analog lanreotide in healthy volunteers. Clin Pharmacol Ther. 1999 Apr;65(4):413-9.</citation>
    <PMID>10223779</PMID>
  </reference>
  <reference>
    <citation>Lamrani A, Vidon N, Sogni P, Nepveux P, Catus F, Blumberg J, Chaussade S. Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans. Br J Clin Pharmacol. 1997 Jan;43(1):65-70.</citation>
    <PMID>9056054</PMID>
  </reference>
  <reference>
    <citation>Ludlam WH, Anthony L. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. Adv Ther. 2011 Oct;28(10):825-41. doi: 10.1007/s12325-011-0062-9. Epub 2011 Sep 28. Review.</citation>
    <PMID>21964965</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2014</study_first_submitted>
  <study_first_submitted_qc>January 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <last_update_submitted>January 31, 2014</last_update_submitted>
  <last_update_submitted_qc>January 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Kim Moubax</investigator_full_name>
    <investigator_title>Dr. Kim Moubax, gastro-enterology</investigator_title>
  </responsible_party>
  <keyword>Bile reflux</keyword>
  <keyword>Reflux esophagitis</keyword>
  <keyword>Lanreotide autogel</keyword>
  <keyword>Somatuline</keyword>
  <keyword>Endoscopy</keyword>
  <keyword>Impedancemetry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
    <mesh_term>Heartburn</mesh_term>
    <mesh_term>Bile Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

